Pharmaceuticals, Biotechnology and Life Sciences
– In a Phase 1b trial, COR388 reduced levels of fragmented ApoE protein in cerebrospinal fluid of subjects with Alzheimer’s…
New data from electroencephalography (EEG) recordings showed 76% of Dravet syndrome (DS) mice treated with STK-001 were seizure free compared…
Results from Phase 1b/2 CARTITUDE-1 to premiere in oral presentation at the American Society of Hematology Annual Meeting (Abstract #577)…
Follow-up data from Phase 3 E1912 study (Abstract #33) evaluating the investigational use of ibrutinib in combination with rituximab versus…
NDA Submission for Accelerated Approval of Tazemetostat for Patients with Relapsed or Refractory Follicular Lymphoma on Track for December 2019…
– Oral Presentation at the American Society of Hematology (ASH) Annual Meeting on December 7, 2019 – CAMBRIDGE, Mass. &…
Conference Call to Discuss Clinical Program Scheduled for December 12th DUBLIN, Ireland & BURLINGAME, Calif.–(BUSINESS WIRE)–ALX Oncology, a clinical-stage immuno-oncology…
– The first two patients treated with the 3e13 vg/kg dose achieved stable Factor VIII (FVIII) levels demonstrating durability in…
– Mosunetuzumab data to be presented at the American Society of Hematology 2019 Annual Meeting Plenary Scientific Session demonstrate durable…
Duvelisib Achieves Overall Response Rate of 62% in Patients with Relapsed or Refractory PTCL with Manageable Safety Profile in Initial…